Proteomics. Clinical applications
-
Proteomics Clin Appl · Dec 2017
The Proteome of Ulcerative Colitis in Colon Biopsies from Adults - Optimized Sample Preparation and Comparison with Healthy Controls.
The purpose of the study was to optimize the sample preparation and to further use an improved sample preparation to identify proteome differences between inflamed ulcerative colitis tissue from untreated adults and healthy controls. ⋯ The optimized sample preparation method will improve future proteomic studies on colon mucosa. The observed protein abundance changes and their enrichment in various groups improve our understanding of ulcerative colitis on protein level.
-
Proteomics Clin Appl · Dec 2016
ReviewProteomics and molecular tools for unveiling missing links in the biochemical understanding of schizophrenia.
Psychiatric disorders are one of the biggest burdens to society, with significant personal and economical costs. Schizophrenia (SCZ), among them, is still poorly understood, and its molecular characterization is crucial to improve patients' diagnosis and treatment. ⋯ From postmortem brain to animal models and cell culture, new tools are emerging, including recent advances in proteomics, and there is a need to apply them to solve these problems. Here, we review some of those features, mainly related to where proteomics could help, and discuss whether those new technologies could and should be applied to psychiatric disorder studies.
-
Proteomics Clin Appl · Aug 2016
ReviewClinically-oriented proteomic investigation of sickle cell disease: Opportunities and challenges.
Sickle cell disease (SCD) is an autosomal recessively inherited β-hemoglobinopathy causing a sickling hemoglobin (HbS) to be expressed in the erythrocyte. Due its unique biophysical properties and tendency to form polymers in deoxygenated conditions, HbS causes dramatic erythrocyte deformation and damage ultimately leading to diffuse hemolysis, vasco-occlusion, and vasculopathy in affected individuals. Albeit SCD was the first molecular disease identified in the human several decades ago, the progress in caring for patients with SCD has been globally limited and faces considerable biological, medical, psychological, and economic challenges. ⋯ It also establishes a tentative conceptual framework for clinically oriented investigations. The ultimate target is the translation of findings into validated and actionable improvements at the bedside. Thanks to significant technological advances, proteomics is poised to play an important role for patients affected by hematological disorders, and SCD could be a paradigm for impactful research.
-
Proteomics Clin Appl · Oct 2015
Closing the gap between brain banks and proteomics to advance the study of neurodegenerative diseases.
Neurodegenerative diseases (NDs), such as Alzheimer's disease and Parkinson's disease, are among the most debilitating neurological disorders, and as life expectancy rises quickly around the world, the scientific and clinical challenges of dealing with them will also increase dramatically, putting increased pressure on the biomedical community to come up with innovative solutions for the understanding, diagnosis, and treatment of these conditions. Despite several decades of intensive research, there is still little that can be done to prevent, cure, or even slow down the progression of NDs in most patients. ⋯ One way to do this is to apply the tools of proteomics to well-characterized samples of human brain tissue, but a closer partnership must still be forged between proteomic scientists, brain banks, and clinicians to explore the maximum potential of this approach. Here, we analyze the challenges and potential benefits of using human brain tissue for proteomics research toward NDs.
-
Proteomics Clin Appl · Dec 2014
ReviewProteomic and biomarker studies and neurological complications of pediatric sickle cell disease.
Biomarker analysis and proteomic discovery in pediatric sickle cell disease has the potential to lead to important discoveries and improve care. The aim of this review article is to describe proteomic and biomarker articles involving neurological and developmental complications in this population. A systematic review was conducted to identify relevant research publications. ⋯ Positive findings include increases in plasma brain-derived neurotrophic factor and platelet-derived growth factor with elevated transcranial Dopplers velocities, increases in platelet-derived growth factor isoform AA with overt stroke, and increases in glial fibrillary acidic protein with acute brain injury. These promising potential neuro-biomarkers provide insight into pathophysiologic processes and clinical events, but their clinical utility is yet to be established. Additional proteomics research is needed, including broad-based proteomic discovery of plasma constituents and blood cell proteins, as well as urine and cerebrospinal fluid components, before, during and after neurological and developmental complications.